Abstract
Objective To determine whether screening clinically low-risk singleton pregnancies with a validated maternal blood test for preterm birth (PTB) risk, then providing preventive treatments for those at higher risk, will improve neonatal outcomes compared to a large historical population.
Methods The AVERT PRETERM trial (NCT03151330) took place from June 2018-September 2020 at ChristianaCare Hospital (Newark, DE). Women with singleton non-anomalous pregnancies and no PTB history were prospectively enrolled, screened at 191/7-206/7 weeks gestation with a maternal circulating biomarker test for spontaneous PTB (sPTB) risk, and followed through neonatal hospital discharge. Those identified at higher risk (≥16.0%, approximately twice the U.S. population risk) were offered vaginal progesterone (200 mg) and aspirin (81 mg) daily, and care management comprising increased patient outreach and education. Outcomes were compared for prospective arm participants who screened either “not-higher-risk” or “higher-risk accepting treatment” (modified intent-to-treat population) with those in a ChristianaCare historical arm of 10000 pregnancies. Co-primary outcomes were: neonatal morbidity and mortality, as measured by a composite neonatal morbidity index (NMI) score integrating medical complications with neonatal intensive care unit (NICU) length of stay or death; and neonatal hospital length of stay (NNLOS). Cox proportional hazards survival analysis and ordinal logistic regression were used to evaluate outcomes and control for differences between arms.
Results A COVID-prompted research shutdown occurred when 1460 biomarker-screened individuals had reached 37 weeks’ gestation in a racially diverse prospective arm. Of these, 34.7% (507/1460) had biomarker scores indicating higher risk, with 56.4% (286/507) accepting intervention and 43.6% (221/507) declining. The remaining 65.3% (953/1460) were designated not-higher-risk. Prospective arm neonates had lower NMI scores (odds ratio, 0.81, 95% CI, 0.67-0.98, P=0.031), and severe neonatal morbidity (NMI ≥3) was reduced by 18% compared to historical controls. Neonatal hospital stays also were shorter (hazard ratio, 1.35, 95% CI, 1.08-1.70, P=0.01), with average NNLOS decreasing by 21% in a quantile of longest stays.
Conclusion Improved neonatal outcomes after biomarker PTB risk stratification and preventive care management for higher-risk individuals suggests a test-and-treatment strategy that can ameliorate PTB complications and associated medical, societal and economic burdens in a previously unidentifiable patient population: singleton, often nulliparous, pregnancies deemed clinically low risk.
Trial registration ClinicalTrials.gov #NCT03151330 (https://www.clinicaltrials.gov/study/NCT03151330)
Funding Source Sera Prognostics, Inc.
Competing Interest Statement
BS, JS, and MGW are paid consultants of Sera Prognostics, Inc. For the purposes of this study, JS and MGW reported to MKH and were paid consultants of ChristianaCare, and BS was supported by Sera Prognostics, Inc. MKH received an investigator-initiated grant from Sera Prognostics, Inc., to conduct this study.
Clinical Trial
NCT03151330
Clinical Protocols
https://www.clinicaltrials.gov/study/NCT03151330
Funding Statement
This study was funded by Sera Prognostics, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol (NCT03151330) was approved by the ChristianaCare institutional review board prior to participant enrollment. An independent data and safety monitoring board convened prior to study initiation, approved the protocol, and provided oversight of adverse events. All participants provided written informed consent, and all authors accept responsibility for the accuracy and completeness of the data and for fidelity in the conduct of the trial.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial Support Sera Prognostics, Inc.
ClinicalTrials.gov Registration NCT03151330
This version of the manuscript has been updated to include additional analyses and to revise presentation.
Data Availability
Data supporting the results presented here are available on request from the corresponding author. Data will not be made publicly available or in any format that may violate a subject's right to privacy. For example, dating information or identifiers that could allow data integration, thereby enabling potential identification of study subjects, are protected.